C-Myc immunohistochemistry in diffuse large B cell lymphoma

Research output: Contribution to journalArticle

Abstract

Diffuse large B cell lymphoma is a collection of different biologic entities with a common appearance but different clinical behaviors. The MYC oncogene is mutated in a subset of diffuse large B cell lymphoma and is also mutated in related entities such as Burkitt lymphoma. Recently, an antibody to the c-Myc oncoprotein has become available for immunohistochemistry, raising the possibility of a rapid, reproducible and inexpensive measure of MYC abnormality. Initial retrospective studies of these lymphomas suggest that the c-Myc status is clinically important for diagnosis and prognosis, particularly when used in conjunction with BCL2 immunohistochemistry. It is possible that therapy will be modified based in part on c-Myc status, once the appropriate prospective studies have been performed.

Original languageEnglish (US)
Pages (from-to)234-238
Number of pages5
JournalPathology Case Reviews
Volume19
Issue number5
DOIs
Publication statusPublished - Dec 10 2014

    Fingerprint

Keywords

  • BCL2
  • Diffuse large B cell lymphoma
  • DLBCL
  • Immunohistochemistry
  • MYC

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this